| Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... New England Journal of Medicine 375 (19), 1823-1833, 2016 | 10035 | 2016 |
| Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer L Gandhi, D Rodríguez-Abreu, S Gadgeel, E Esteban, E Felip, ... New England journal of medicine 378 (22), 2078-2092, 2018 | 6151 | 2018 |
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... The lancet oncology 13 (3), 239-246, 2012 | 6137 | 2012 |
| Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC MA Socinski, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ... New England Journal of Medicine 378 (24), 2288-2301, 2018 | 3601 | 2018 |
| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2614 | 2017 |
| Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater M Reck, D Rodríguez–Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... Journal of Clinical Oncology 37 (7), 537-546, 2019 | 1528 | 2019 |
| Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer S Gadgeel, D Rodríguez-Abreu, G Speranza, E Esteban, E Felip, ... Journal of clinical oncology 38 (14), 1505-1517, 2020 | 1012 | 2020 |
| Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in … M Reck, TSK Mok, M Nishio, RM Jotte, F Cappuzzo, F Orlandi, ... The Lancet Respiratory Medicine 7 (5), 387-401, 2019 | 929 | 2019 |
| Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50% M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... Journal of Clinical Oncology 39 (21), 2339-2349, 2021 | 770 | 2021 |
| Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ... The Lancet Oncology 21 (11), 1413-1422, 2020 | 707 | 2020 |
| Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... Lancet Oncol 13 (3), 239-246, 2012 | 608 | 2012 |
| Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study CM Rudin, MM Awad, A Navarro, M Gottfried, S Peters, T Csőszi, ... Journal of Clinical Oncology 38 (21), 2369-2379, 2020 | 579 | 2020 |
| Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial R Jotte, F Cappuzzo, I Vynnychenko, D Stroyakovskiy, ... Journal of Thoracic Oncology 15 (8), 1351-1360, 2020 | 500 | 2020 |
| Perioperative pembrolizumab for early-stage non–small-cell lung cancer H Wakelee, M Liberman, T Kato, M Tsuboi, SH Lee, S Gao, KN Chen, ... New England Journal of Medicine 389 (6), 491-503, 2023 | 471 | 2023 |
| Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 D Rodríguez-Abreu, SF Powell, MJ Hochmair, S Gadgeel, E Esteban, ... Annals of Oncology 32 (7), 881-895, 2021 | 405 | 2021 |
| Epidemiology of hematological malignancies D Rodriguez-Abreu, A Bordoni, E Zucca Annals of oncology 18, i3-i8, 2007 | 394 | 2007 |
| Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open … JR Brahmer, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... The Lancet Oncology 18 (12), 1600-1609, 2017 | 372 | 2017 |
| IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC MA Socinski, M Nishio, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ... Journal of Thoracic Oncology 16 (11), 1909-1924, 2021 | 349 | 2021 |
| Immune checkpoint inhibitors: review and management of endocrine adverse events E González-Rodríguez, D Rodríguez-Abreu, ... The oncologist 21 (7), 804-816, 2016 | 289* | 2016 |
| Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up … BC Cho, DR Abreu, M Hussein, M Cobo, AJ Patel, N Secen, KH Lee, ... The Lancet Oncology 23 (6), 781-792, 2022 | 267 | 2022 |